Turn Therapeutics Q2 net loss per share widens on higher R&D costs

Turn Therapeutics

12/08/2026 21:39

Overview
US biotechnology firm's Q2 net loss per share widened yr/yr as R&D expenses increased
Company expanded GX-03 Phase 2 study after interim analysis showed efficacy in broader patient group
Former FDA Commissioner Dr. Stephen Hahn appointed Executive Clinical and Regulatory Lead during Q2

Outlook
Company expects to complete GX-03 Phase 2 enrollment by end of 2026
Turn targets first patient dosing in hidradenitis suppurativa study for Q2 2027
Company expects cash to fund operations into Q3 2027

Result Drivers
R&D SPENDING - Increased research and development expenses driven by expanded Phase 2 trial activity for GX-03
TRIAL EXPANSION - Company expanded GX-03 Phase 2 study after interim analysis showed efficacy in a broader atopic dermatitis patient group

Company press release: ID:nBw59J7n7a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.20
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Turn Therapeutics Inc is $16.08, about 57.3% above its August 11 closing price of $10.22

Reuters Recommended Reads
Aug 10 - Oruka Therapeutics Q2 net loss widens on higher R&D costs
Aug 11 - Taysha Gene Therapies Q2 net loss widens on higher R&D costs
Aug 10 - MoonLake's psoriatic arthritis drug meets key goals in late-stage trial

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)